Takeda Pharmaceutical Company Limited Asset Resilience Ratio
Takeda Pharmaceutical Company Limited asset resilience ratio. Takeda Pharmaceutical Company Limited (TKDA) has an Asset Resilience Ratio of 0.69% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read TKDA total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Takeda Pharmaceutical Company Limited (2017–2025)
Asset resilience ratio of Takeda Pharmaceutical Company Limited from 2017 to 2025. This chart shows how Takeda Pharmaceutical Company Limited's Asset Resilience Ratio has changed over time. See free cash flow generation of Takeda Pharmaceutical Company Limited to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Takeda Pharmaceutical Company Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Takeda Pharmaceutical Company Limited.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €107.00 Billion | 0.69% |
| Total Liquid Assets | €107.00 Billion | 0.69% |
Asset Resilience Insights
- Limited Liquidity: Takeda Pharmaceutical Company Limited maintains only 0.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Takeda Pharmaceutical Company Limited Industry Peers by Asset Resilience Ratio
Compare Takeda Pharmaceutical Company Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
Northeast Pharmaceutical Group Co Ltd
SHE:000597 |
Drug Manufacturers - Specialty & Generic | 1.64% |
|
Tianjin Tianyao Pharmaceuticals Co Ltd
SHG:600488 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Takeda Pharmaceutical Company Limited Asset Resilience Ratio by Year (2017–2025)
Takeda Pharmaceutical Company Limited asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Takeda Pharmaceutical Company Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.14% | €20.48 Billion ≈ $23.94 Billion |
€14.25 Trillion ≈ $16.66 Trillion |
+0.04pp |
| 2024-03-31 | 0.10% | €15.09 Billion ≈ $17.64 Billion |
€15.11 Trillion ≈ $17.66 Trillion |
-0.04pp |
| 2023-03-31 | 0.14% | €20.17 Billion ≈ $23.59 Billion |
€13.96 Trillion ≈ $16.32 Trillion |
-0.05pp |
| 2022-03-31 | 0.19% | €25.30 Billion ≈ $29.58 Billion |
€13.18 Trillion ≈ $15.41 Trillion |
-0.09pp |
| 2021-03-31 | 0.28% | €36.60 Billion ≈ $42.79 Billion |
€12.91 Trillion ≈ $15.10 Trillion |
+0.16pp |
| 2020-03-31 | 0.12% | €15.82 Billion ≈ $18.50 Billion |
€12.82 Trillion ≈ $14.99 Trillion |
-0.04pp |
| 2019-03-31 | 0.17% | €23.28 Billion ≈ $27.21 Billion |
€13.87 Trillion ≈ $16.22 Trillion |
-1.80pp |
| 2018-03-31 | 1.96% | €80.65 Billion ≈ $94.28 Billion |
€4.11 Trillion ≈ $4.80 Trillion |
+0.66pp |
| 2017-03-31 | 1.30% | €56.68 Billion ≈ $66.27 Billion |
€4.36 Trillion ≈ $5.09 Trillion |
-- |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more